Collaboration. Acceleration. Results.
Myelin Repair Foundation Home Page
UPDATE: MRF launches innovative effort to identify biomarkers to speed myelin repair drug development and clinical trials.

Research Model

The Myelin Repair Foundation pioneered the Accelerated Research Collaboration™ (ARC™) model which addresses every phase in the drug discovery continuum, from initial research all the way to licensing by commercial drug developers.

The Accelerated Research Collabortation™ (ARC™) Model

Click each section to learn more about the Myelin Repair Foundation's ARC model.

Patient Outcomes
Clinical Development
Clinical Development
Clinical Development
Translational Medicine Platform
Translational Medicine Platform
Translational Medicine Platform
Discovery Biology
Discovery Biology
Discovery Biology

What Others are Saying

“[The Myelin Repair Foundation’s approach] could result in a promising future for big pharma, a sustainable future for the biomedical innovation ecosystem, and most importantly, a healthier future for patients.”

The Atlantic
April 2012

Focus on Biomarkers

The Myelin Repair Foundation is identifying biomarkers to help accelerate myelin repair treatments. Learn more about the importance of biomarkers and the role they play in getting treatments to patients.